Citations 2
S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
Patriarca, Andrea, Rivera, Candido E., Granacher, Nikki, Palmer, Jeanne , Rampal, Raajit K. , Eliane, Jean-Pierre, Chang, Tzuu-Wang, Klein, Sandra, Colak, Gozde , Harrison, Claire , Passamonti, Francesco , Patriarca, Andrea , Knapper, Steven , Scandura, Joseph Michael , Devos, Timothy , Mead, Adam J. , Oh, Stephen T. , Teichmann, Lino Lars , Li, Qing
HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e9927843
Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
Kremyanskaya, Marina , Rampal, Raajit K. , Patriarca, Andrea, Zavidij, Oksana, Chang, Tzuu-Wang, Taverna, Pietro, Harrison, Claire , Scandura, Joseph Michael , Verstovšek, Srđan , Talpaz, Moshe , Vannucchi, Alessandro M. , Gupta, Vikas , Palandri, Francesca , Patriarca, Andrea , Bose, Prithviraj , Chen, Dong , Cui, Jike , Mascarenhas, John
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1523-1525